Skip
UTPhysicians logoUT Physicians - a part of UTHealth
By invitation only, a COVID-19 vaccine is currently available to priority at-risk patients. Learn more.

888-4UT-DOCS | 888-488-3627

  • About Us
    About UT Physicians Careers Contact Us News Health Programs/Services Patient Stories Videos
  • Find a Provider / Clinic
    Search By Specialty Search Providers Search By Name Search By Location
  • Patient Information
    About your Visit Billing Information Clinical Trials Insurance Refer a patient Make an Appointment International Patients Medical Records Legal Billing Records
  • Health Programs/Services
  • Make an Appointment
  • Pay My Bill
  • MyUTP Portal
  • Careers

New chemotherapy drug studied for malignant brain tumor in children

Written by: Deborah Mann Lake | Updated: May 11, 2020
Find a Physician / Clinic
  • Search By Specialty
  • Search Providers
  • Search By Name
  • Search By Location
UTHealth neurosurgeon David Sandberg, MD, is leading a clinical trial investigating a new formulation of panobinostat for malignant pediatric brain tumors. (Photo by Children's Memorial Hermann Hospital)

UTHealth neurosurgeon David Sandberg, MD, is leading a clinical trial investigating a new formulation of panobinostat for malignant pediatric brain tumors. (Photo by Children's Memorial Hermann Hospital)

MTX110 is a new formulation of panobinostat, a chemotherapy drug that has shown promise in laboratory models of medulloblastoma, the most common malignant brain tumor in children. Now, MTX110 is the focus of a novel trial that places the therapy directly into the fourth ventricle of the brain to treat patients with recurrent medulloblastoma.

According to the American Cancer Society, about 500 children are diagnosed with medulloblastoma every year. Patients undergo surgery and then receive radiation therapy and chemotherapy. Current treatments are often associated with considerable toxicity, and when tumors recur despite these treatments, survival rates are low.

“The current treatments for children and adults with medulloblastoma are inadequate,” said David Sandberg, MD, director and Dr. Marnie Rose Professor in Pediatric Neurosurgery at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth). “Children have low survival rates despite salvage therapy, and novel approaches are needed. This is a new trial with a novel drug and we are very hopeful that we can help patients with this devastating disease.”

The pilot study, which has been approved by the Food and Drug Administration, will enroll five patients with recurrent medulloblastoma at Children’s Memorial Hermann Hospital. MTX110 is a new formulation of panobinostat from Midatech Pharma PLC.

This study is listed at ClinicalTrials.gov under NCT04315064 (https://clinicaltrials.gov/ct2/show/NCT04315064). For more information, please contact Bangning Yu, RN (Bangning.Yu@uth.tmc.edu, 713-500-7363).


Share

All Articles
  • Cardiothoracic & Vascular Surgery
  • Children's Health Stories
  • Coronavirus
  • Coronavirus Español
  • COVID-19 Patient Resources
  • Ear, Nose, and Throat Stories
  • Epilepsy
  • Featured
  • Heart Care
  • In the Media
  • In the Media Español
  • News
  • Orthopedics
  • Patient Stories
  • Pediatric Surgery
  • UTHealth COVID-19 Research
  • UTHealth Research
  • Women's Health Stories

UT Physicians A part of UTHealth

UT Professional Building
6410 Fannin Street | Houston, Texas 77030
888-4UT-DOCS (888-488-3627)

UT Physicians - facebook UT Physicians - instagram UT Physicians - twitter UT Physicians - linkedin UT Physicians - youtube

UT PHYSICIANS APP NOW AVAILABLE FOR DOWNLOAD

Downlaod the UT Physicians App on the Apple Store
Downlaod the UT Physicians App on Google Play

AN OFFICIAL ORTHOPEDIC AND SPORTS MEDICINE PROVIDER FOR

Houston Dynamo Logo
Houston Dash Logo

THE CLINICAL PRACTICE OF

McGovern Medical School at UTHealth
Contact / Feedback | Report Error | Patient Privacy | Web File Viewing | Site Policies | Employee Links

Copyright © 2018 to Present – The University of Texas Health Science Center at Houston (UTHealth)